potravitug
BK Polyomavirus (BKPyV) infection in kidney transplant recipients
Key Facts
About Memo Therapeutics
Memo Therapeutics AG is a clinical-stage biotechnology company developing best-in-class therapeutic antibodies derived from the immune systems of elite responders—patients who mount exceptionally potent natural immune responses to viruses or cancer. The company's proprietary DROPZYLLA® technology platform enables the high-fidelity mining of antibody repertoires to isolate highly potent candidates. With its lead asset, potravitug, in a pivotal Phase II trial for BK polyomavirus infection and a partnered oncology pipeline, Memo is positioned to address significant unmet needs in transplantation and oncology. The company operates as a private entity, leveraging strategic partnerships to advance its programs.
View full company profile